icometrix

Detect and monitor ARIA-E and ARIA-H in Alzheimer’s MRI with icobrain aria. Automated detection of amyloid-related imaging abnormalities supports clinicians and researchers.

As of January 1, 2024, CPT codes 0865T and 0866T, approved by the American Medical Association, cover icobrain’s quantitative brain MRI analysis, including lesion detection and brain volume quantification. Over 30 U.S. insurers already reimburse for the service.

icobrain ep uses AI to analyze brain MRI in epilepsy, providing objective insights to support diagnosis, surgical planning, and follow-up.

icobrain ms delivers AI-driven MRI analysis for multiple sclerosis, providing objective insights for diagnosis, disease monitoring, and treatment evaluation.

A 2021 study evaluated icobrain dm’s diagnostic value for Alzheimer’s disease in routine practice, comparing it to FreeSurfer. The results suggested automated volumetric tools improve diagnostic certainty for Alzheimer’s when combined with brain volume measurements.

icometrix published clinical validation of icobrain aria in *JAMA Open Network*, demonstrating its role in monitoring amyloid-related imaging abnormalities (ARIA) for Alzheimer’s disease treatments. The software helps guide dosing and continuation decisions for new therapies.

The American College of Radiology and icometrix collaborated to improve Alzheimer’s disease care by integrating icometrix’s AI-based MRI quantification software. The partnership supports safe prescription of new FDA-approved treatments.

Baptist Health in Arkansas became the first healthcare organization to adopt icometrix’s AI technology, deploying icobrain software across its imaging locations. The software analyzes brain MRI scans with high precision to enhance neuroradiology services.

icometrix raised $18 million in 2019 to advance its AI solutions for brain MRI and CT analysis. The company’s icobrain software, CE-marked and FDA-cleared, extracts clinically meaningful data from scans to support patient care.

icometrix and Queen Mary University of London received an AI Award from the National Institute for Health and Care Research (NIHR) to study AI’s impact on MRI for multiple sclerosis care.

icometrix develops AI-powered brain imaging software, including icobrain, for diagnosing and monitoring conditions like multiple sclerosis, dementia, and traumatic brain injury. The company’s solutions aim to improve clinical efficiency and care quality.

icobrain is an FDA-cleared and CE-marked AI neuroimaging tool used by hospitals and researchers worldwide. It provides clinically validated, disease-specific reports to support radiologists in diagnosing and monitoring neurological conditions.

The Multiple Sclerosis Association of America (MSAA) and icometrix (now part of GE HealthCare) are collaborating to expand the **MRI Access Program**, improving MRI availability and equity for people with multiple sclerosis (MS). The initiative leverages icometrix’s AI-driven neuroimaging solutions to enhance diagnostic and monitoring capabilities for MS patients. This partnership aims to address gaps in access to critical imaging services for underserved communities.

Jun 2026MSAANews article

GE HealthCare acquires Icometrix to integrate its AI-powered brain MRI software, which detects side effects from recently launched Alzheimer’s treatments. The software aids in monitoring neurological responses to emerging therapies. The deal expands GE’s diagnostic imaging capabilities in neurodegenerative disease management.

Sep 2025MedTech DiveNews article

Icometrix’s **Icobrain Aria** receives FDA 510(k) clearance as an automated software tool for **ARIA (Automated Response Imaging Analysis)** monitoring. The solution aids clinicians in analyzing brain imaging data, supporting early detection and assessment of neurological conditions. Icometrix, based in Boston, develops AI-driven neuroimaging software for clinical workflows.

Nov 2024Practical NeurologyNews article

Icobrain’s **Aria** becomes the first AI tool cleared by the FDA for detecting **ARIA-E** and **ARIA-H**—side effects linked to Alzheimer therapies. The software analyzes brain MRI scans to automate severity grading, improving safety monitoring for emerging treatments. Developed using thousands of scans, Aria aids clinicians in identifying risks during clinical trials and patient care.

Nov 2024neurologylive.comNews article